|Articles|February 8, 2022

Tempus Acquires Highline Sciences

Acquisition of oncology CRO will expand upon existing partnerships.

Tempus has announced the acquisition of Highline Sciences, a ​​CRO focused on oncology.

Highline Sciences manages and executes on early and late-stage clinical trials. Highline’s capabilities will help support and grow new and established business lines within Tempus, allowing the company to vertically integrate more clinical trial services when appropriate to complement its existing CRO partnerships.

Read more about this new partnership here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content